[Nikavir (phosphazide)--an antiretroviral agent: anti-HIV activity, toxicology, pharmacokinetics and some perspectives of its clinical use].
Nikavir (phosphazide) is an antiretroviral agent of the class of inhibitors of type 1 HIV reverse transcriptase. It was designed in Russia and is currently used in the medical practice for the treatment of HIV infection as the monotherapy or as a component of the combined therapy. It is characterized by high anti-HIV activity, low cytotoxicity and less frequent induction of HIV-1 variants with lower susceptibility to nikavir, as compared to azidothymidine. Unlike azidothymidine, nikavir induces no blood count shifts in the patients and belongs to the group of low toxic compounds. The tolerance of nikavir by HIV-infected patients is good and its therapeutic action in HIV-1 infection is marked.
Galegov
G A
GA
D000284:Administration, Oral; D000818:Animals; D044966:Anti-Retroviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001386:Azides / Q000494:pharmacology* / Q000627:therapeutic use; D002214:Capsules; D002460:Cell Line; D002986:Clinical Trials as Topic; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D015658:HIV Infections / Q000188:drug therapy; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D007928:Lethal Dose 50; D008297:Male; D063065:Organophosphonates / Q000494:pharmacology* / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D013607:Tablets; D013936:Thymidine / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use
C405002:3'-azido-3'-deoxythymidine-5'-H-phosphonate; D044966:Anti-Retroviral Agents; D001386:Azides; D002214:Capsules; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D013607:Tablets; D013936:Thymidine